N. Lynn Henry

12.1k total citations · 4 hit papers
208 papers, 8.1k citations indexed

About

N. Lynn Henry is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, N. Lynn Henry has authored 208 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Oncology, 67 papers in Cancer Research and 63 papers in Genetics. Recurrent topics in N. Lynn Henry's work include Estrogen and related hormone effects (56 papers), Breast Cancer Treatment Studies (50 papers) and Cancer Treatment and Pharmacology (49 papers). N. Lynn Henry is often cited by papers focused on Estrogen and related hormone effects (56 papers), Breast Cancer Treatment Studies (50 papers) and Cancer Treatment and Pharmacology (49 papers). N. Lynn Henry collaborates with scholars based in United States, Canada and United Kingdom. N. Lynn Henry's co-authors include Daniel F. Hayes, Vered Stearns, David A. Flockhart, Anna Maria Storniolo, Arti Hurria, Patricia A. Ganz, Ellen Warner, Corinne R. Leach, Samuel J. LaMonte and Mandi L. Pratt‐Chapman and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

N. Lynn Henry

187 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

2011 1.5k citations N. Lynn Henry, Daniel F. Hayes et al. profile →
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline

2015 734 citations N. Lynn Henry, Patricia A. Ganz et al. Journal of Clinical Oncology profile →
Cancer biomarkers

2012 569 citations N. Lynn Henry, Daniel F. Hayes profile →
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline

2015 509 citations N. Lynn Henry, Patricia A. Ganz et al. profile →

Peers

Countries citing papers authored by N. Lynn Henry

Since Specialization

Citations

This map shows the geographic impact of N. Lynn Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Lynn Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Lynn Henry more than expected).

Fields of papers citing papers by N. Lynn Henry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Lynn Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Lynn Henry. The network helps show where N. Lynn Henry may publish in the future.

Co-authorship network of co-authors of N. Lynn Henry

This figure shows the co-authorship network connecting the top 25 collaborators of N. Lynn Henry. A scholar is included among the top collaborators of N. Lynn Henry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Lynn Henry. N. Lynn Henry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Play Together? Unveiling Facilitators and Barriers to Inclusive Outdoor Play for Dutch Children With and Without Disabilities: A Qualitative Study 2025 ·Child Care Health and Development ·(unknown), (unknown), Jan Willem Gorter, N. Lynn Henry, Kirsten Visser, Harriët Wittink, (unknown), (unknown), Manon Bloemen	0
2	Clinician and Patient Perspectives on a Patient-Facing Online Breast Cancer Symptom Visualization Tool 2025 ·JCO Clinical Cancer Informatics ·Gillian Gresham, Michael Luu, N. Lynn Henry, (unknown), (unknown), Greg Yothers, Sungjin Kim, André Rogatko, Deanna J. Attai, Mourad Tighiouart, Ron D. Hays, Patricia A. Ganz	1
3	A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009. 2024 ·Journal of Clinical Oncology ·Sandra M. Swain, (unknown), Shannon L. Puhalla, Patricia A. Ganz, N. Lynn Henry, Reena S. Cecchini, Sonya Reid, Priya Rastogi, Charles E. Geyer, Julia White, Amy S. Clark, Tufia C. Haddad, Gregory A. Vidal, Norman Wolmark, Eleftherios P. Mamounas	3
4	TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer 2024 ·JCO Precision Oncology ·Christos Vaklavas, Cindy Matsen, Zhengtao Chu, Kenneth M. Boucher, Sandra D. Scherer, Satya S. Pathi, Anna C. Beck, Kirstyn E. Brownson, Saundra S. Buys, (unknown), (unknown), H. Evin Gulbahce, N. Lynn Henry, Stephen Kimani, (unknown), (unknown), John H. Ward, Mei Wei, Bryan E. Welm, Alana L. Welm	3
5	The impact of cannabidiol (CBD) on aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Kelley M. Kidwell, Kelly Scheu, Kathleen Kemmer, Kevin F. Boehnke, N. Lynn Henry	1
6	Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data 2024 ·JCO Clinical Cancer Informatics ·Michael Luu, Gillian Gresham, N. Lynn Henry, Sungjin Kim, André Rogatko, Greg Yothers, Ron D. Hays, Mourad Tighiouart, Patricia A. Ganz	3
7	Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights 2024 ·JCO Oncology Practice ·Igor Makhlin, Lesley Fallowfield, N. Lynn Henry, Harold J. Burstein, Mark R. Somerfield, Angela DeMichele	8
8	Adverse health outcomes among rural prostate cancer survivors: A population-based study 2023 ·Cancer Epidemiology ·(unknown), (unknown), Michael Newman, Vikrant Deshmukh, John Snyder, (unknown), (unknown), Shane Lloyd, N. Lynn Henry, Brock O’Neil, Mia Hashibe	1
9	Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use 2023 ·Clinical Breast Cancer ·(unknown), Yajing Li, Kelley M. Kidwell, N. Lynn Henry	6
10	Risk of Toxicity From Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), Amy L. Pasternak, N. Lynn Henry, Vaibhav Sahai, Daniel L. Hertz	2
11	A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol 2022 ·Technology in Cancer Research & Treatment ·(unknown), Ken B. Johnson, Bihua Bie, (unknown), (unknown), (unknown), Jennifer Hockings, (unknown), (unknown), (unknown), (unknown), Jennifer DeVecchio, (unknown), Mei Wei, G. Thomas Budd, N. Lynn Henry, Charis Eng, Joseph Foss, Daniel M. Rotroff	7
12	Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias 2021 ·JNCI Cancer Spectrum ·Patrick Schnell, Maryam B. Lustberg, N. Lynn Henry	2
13	Disparities in Cardiovascular Disease Risk Among Hispanic Breast Cancer Survivors in a Population-Based Cohort 2021 ·JNCI Cancer Spectrum ·Qingqing Hu, (unknown), Kerry Rowe, John Snyder, Vikrant Deshmukh, Michael Newman, Alison Fraser, Ken R. Smith, Lisa H. Gren, Christina A. Porucznik, Joseph B. Stanford, David K. Gaffney, N. Lynn Henry, (unknown), Mia Hashibe	11
14	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms 2021 ·JNCI Cancer Spectrum ·N. Lynn Henry, Joseph M. Unger, Cathee Till, Katherine D. Crew, Michael Fisch, Dawn L. Hershman	2
15	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer 2019 ·Cancer Research ·Rachel L. Stewart, (unknown), Rachel E. Factor, N. Lynn Henry, Kenneth M. Boucher, Philip S. Bernard, Katherine E. Varley	35
16	Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy 2018 ·Clinical Cancer Research ·Daniel L. Hertz, Kelley M. Kidwell, (unknown), Feng Li, Manjunath P. Pai, Monika L. Burness, Jennifer J. Griggs, Anne F. Schott, Catherine Van Poznak, Daniel F. Hayes, Elizabeth Smith, N. Lynn Henry	45
17	Integrative Oncology Scholars Program: A Model for Integrative Oncology Education 2018 ·The Journal of Alternative and Complementary Medicine ·Suzanna M. Zick, (unknown), Judith M. Fouladbakhsh, Heather Greenlee, Richard E. Harris, N. Lynn Henry, Shruti Jolly, (unknown), Jane Perlmutter, Tami L. Remington, (unknown), (unknown), Brad Zebrack, (unknown), Rita Benn	12
18	Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy 2015 ·Clinical Cancer Research ·Cesar A. Santa‐Maria, Amanda L. Blackford, Anne Nguyen, Todd C. Skaar, Santosh Philips, Steffi Oesterreich, James M. Rae, Zeruesenay Desta, Jason Robarge, N. Lynn Henry, Anna Maria Storniolo, Daniel F. Hayes, Roger S. Blumenthal, Pamela Ouyang, Wendy S. Post, David A. Flockhart, Vered Stearns	18
19	Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer 2012 ·Journal of Clinical Oncology ·N. Lynn Henry, Faouzi Azzouz, Zereunesay Desta, Lang Li, Anne Nguyen, Suzanne Lemler, Jill A. Hayden, Karineh Tarpinian, (unknown), David A. Flockhart, Vered Stearns, Daniel F. Hayes, Anna Maria Storniolo	284
20	Cytoplasmic Estrogen Receptor in Breast Cancer 2011 ·Clinical Cancer Research ·Allison W. Welsh, Donald R. Lannin, Gregory Young, Mark E. Sherman, Jonine D. Figueroa, N. Lynn Henry, Lisa Rydén, Chungyeul Kim, Richard R. Love, Rachel Schiff, David L. Rimm	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact